Phase I/II Open Label Dose Escalation and Dose Expansion Study of Intravenous Infusion of W0101, an Antibody-drug Conjugate, in Patients With Advanced or Metastatic Solid Tumors. International, Multicenter, Open Label Study
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2019
Price : $35 *
At a glance
- Drugs W 0101 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pierre Fabre
- 31 Aug 2018 Biomarkers information updated
- 18 May 2018 According to a Pierre Fabre media release, this study is led by Principal Investigator Dr. Christophe Massard, head of the Therapeutic Innovation and Early Clinical Trial Department at Gustave Roussy, Villejuif, France.
- 04 Dec 2017 Status changed from not yet recruiting to recruiting.